Phase II evaluation of chlorozotocin in refractory multiple myeloma.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D013311:Streptozocin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; C007028:chlorozotocin; D013311:Streptozocin